Marine Compound Discovery Shows Promise of Improved Drug Treatment for COPD Patients

Published Online: Thursday, January 16, 2014
Follow Pharmacy_Times:
University of Florida pharmacy researchers have isolated a compound from blue-green algae that may inhibit the progression of pulmonary disease.

Related Articles
The flavorings used to improve the taste of electronic cigarettes may pose their own respiratory health hazards.
In a study of patients with comorbid COPD and metabolic syndrome, elevated triglyceride levels were associated with increased mortality rates.
The FDA is reviewing a regulatory application to add an asthma indication to Boehringer Ingelheim’s chronic obstructive pulmonary disease treatment, tiotropium bromide.
Latest Issues
$auto_registration$